A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.77% to 5,606.91 ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.06 per share, missing the Zacks Consensus Estimate of $4.22 per share. This compares to earnings of $4.76 per share a year ago.

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...